Centro Diagnóstico Boris Berenstein has been acquired by DASA
The Berenstein family has sold Centro Diagnóstico Boris Berenstein (CDBB) to Diagnósticos da America S.A. (DASA).
CDBB is among the most respected and well-known diagnostic imaging services in the Brazilian northeast region, focusing on MRIs, TC scans and ultrasound exams. It has six patient service centers, distributed in four different cities in the Recife metropolitan region.
DASA is one of the leading healthcare companies in Brazil, operating the biggest diagnostics business in LatAm with a nation-wide network of high-complexity hospitals, clinics, oncology centers and other healthcare management services. DASA serves more than 20 million patients every year and has around 40,000 employees and 250,000 hired physicians.
One of Oaklins’ teams in Brazil acted as the exclusive financial advisor to the seller and the management of CDBB in the preparation of the sale process and due diligence, the approach and parallel negotiations with potential buyers, and assisted them until closing.
Boris Berenstein
Former Owner and President, Centro Diagnóstico Boris Berenstein
Talk to the deal team
Denis Salvador Morante
Oaklins Fortezza Partners
Related deals
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more